FIA
SGMO

FNY Investment Advisers’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

FNY Investment Advisers’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-513
Closed -$5K – 1144
2019
Q2 		$5K Buy
+513
New +$5.46K ﹤0.01% 702

Other funds holding SGMO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FNY Investment Advisers's SGMO Position: Q3 2019 in Review

FNY Investment Advisers sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2019, closing a stake of 513 shares — an estimated $5K sold.

FNY Investment Advisers first reported a position in SGMO in Q2 2019 and held it in 1 quarter. The position peaked at $5K in Q2 2019. 184 funds tracked by Wall St. Rank hold SGMO as of Q3 2019.

  • FNY Investment Advisers reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 513 SANGAMO THERAPEUTICS INC shares in Q3 2019, an estimated $5K.
  • FNY Investment Advisers first reported a position in SANGAMO THERAPEUTICS INC in Q2 2019 and held it in 1 quarter.
  • FNY Investment Advisers's SANGAMO THERAPEUTICS INC position peaked at $5K in Q2 2019.
  • 184 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2019.

Based on FNY Investment Advisers's 13F filing for Q3 2019, filed 25 Oct 2019.